EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nihon Chouzai Co's EBITDA for the
three
months ended in Sep. 2025 was 円5,120 Mil. Nihon Chouzai Co's Revenue for the
three
months ended in Sep. 2025 was 円97,469 Mil. Therefore, Nihon Chouzai Co's EBITDA margin for the quarter that ended in Sep. 2025 was 5.25%.
Nihon Chouzai Co (TSE:3341) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nihon Chouzai Co EBITDA Margin % Related Terms
Nihon Chouzai Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nihon Chouzai Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nihon Chouzai Co EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Nihon Chouzai Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nihon Chouzai Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nihon Chouzai Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nihon Chouzai Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nihon Chouzai Co (TSE:3341) has a EBITDA Margin % of 5.25% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nihon Chouzai Co and its competitors. This is near median its historical median of 5.76. Over the past decade, Nihon Chouzai Co's EBITDA Margin % has ranged from 3.50 to 7.50.
Is Nihon Chouzai Co's EBITDA Margin % too high?
Nihon Chouzai Co's current EBITDA Margin % of 5.25% is near median its 10-year median of 5.76. Over the past 10 years, this metric has ranged from a low of 3.50 to a high of 7.50. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Nihon Chouzai Co's value of 5.25% is 48.6% below this industry median. Overall, Nihon Chouzai Co has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Nihon Chouzai Co's EBITDA Margin % compare to competitors?
Nihon Chouzai Co's EBITDA Margin % of 5.25% can be compared against companies in the Healthcare Providers & Services industry. The industry median EBITDA Margin % is 10.21. Nihon Chouzai Co's value of 5.25% is 48.6% below this benchmark. Historically, Nihon Chouzai Co's own EBITDA Margin % has ranged from 3.50 to 7.50 over the past decade. While the company's 10-year median is 5.76 vs. the industry median of 10.21, Nihon Chouzai Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nihon Chouzai Co's current EBITDA Margin % of 5.25% is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nihon Chouzai Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nihon Chouzai Co's current EBITDA Margin % is 5.25%, which is near median its own 10-year median of 5.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nihon Chouzai Co stock overvalued right now?
Nihon Chouzai Co (TSE:3341) has a current EBITDA Margin % of 5.25%. The stock's GF Value™ is 円1,563.20, compared to a current price of 円3,925.00 — trading 151.1% above its estimated fair value. The current EBITDA Margin % is 5.25%, which is near median its 10-year median of 5.76 and 48.6% below the Healthcare Providers & Services industry median of 10.21. Nihon Chouzai Co's overall GF Score™ is 51/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nihon Chouzai Co (TSE:3341), the current EBITDA Margin % is 5.25% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nihon Chouzai Co (TSE:3341) Overvalued in 2026?
Based on GuruFocus' analysis, Nihon Chouzai Co stock appears to be overvalued.
The current stock price of 円3,925.00 is trading 151.1% above its estimated GF Value™ of 円1,563.20.
Key valuation signals for TSE:3341:
EBITDA Margin %: 5.25% (near median its 10-year median of 5.76)
GF Value™: 円1,563.20 vs. price of 円3,925.00 (151.1% above fair value)
Industry Position: 48.6% below the Healthcare Providers & Services median
No single metric tells the full story. See the TSE:3341 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nihon Chouzai Co Ltd operates in the pharmaceutical industry. The company is organized into segments: Pharmacy, Pharmaceutical Manufacturing and Sales, and Healthcare Staffing Services and operates mainly from Japan. Through its operating segments, the firm manages a chain of pharmacies nationwide, manufactures and sells generic drugs, and provides staffing services that are specialized in pharmacy.
51GF Score
Get the complete analysis for TSE:3341
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3341 has been successfully added to your 
